This post was originally published on this site Harpoon Therapeutics has granted AbbVie an option for exclusive worldwide rights to HPN217, a treatment candidate for people with multiple myeloma, after the completion of an anticipated Phase 1/2 trial. The companies plan to file an investigational new drug application for HPN217 with the U.S. Food and Drug…
Conditions
Conditions
Bluefield Project to Cure Frontotemporal Dementia Gets $1.2M to Advance FTD Blood Testing
This post was originally published on this site The Bluefield Project to Cure FTD will receive $1.2 million from the Alzheimer’s Drug Discovery Foundation (ADDF) to validate an exploratory blood test in frontotemporal dementia (FTD). The award is the first FTD investment through the foundation’s Diagnostics Accelerator, a venture philanthropy vehicle to advance the development of…
Certain Immune Cells May Drive Sarcoidosis by Producing Inflammatory Agents, Study Suggests
This post was originally published on this site Intermediate monocytes, a type of immune cell, may contribute to the development and progression of sarcoidosis through the production of TARC — a molecule that attracts other specific immune cells linked to inflammation, according to a small study. These findings point to intermediate monocytes and TARC as…
Ygalo Continues to Show Positive Results in RRMM Patients, Oncopeptides Announces
This post was originally published on this site Combination treatment with Ygalo (melflufen) continues to be safe and effective in difficult-to-treat patients with relapsed or refractory multiple myeloma (RRMM), according to the latest results from clinical trials. Data from the clinical program of Ygalo and multiple myeloma’s impact on quality of life will be presented…
Trials into Possible Treatment for Agitation in Alzheimer’s Patients to Continue, Avanir Says
This post was originally published on this site A potential oral treatment for agitation due to Alzheimer’s dementia, AVP-786, will continue in advanced clinical testing after a fuller analysis of data from two completed Phase 3 trials, Avanir Pharmaceuticals said. Their results were conflicting, with one trial showing a significant easing of agitated behaviors in patients given a…
First Patient Dosed in INmune Bio’s Phase1b Trial Testing XPro1595 Anti-inflammatory Compound for Alzheimer’s
This post was originally published on this site INmune Bio has dosed the first patient in its Phase 1b trial (NCT03943264) testing the safety and efficacy of its next-generation anti-inflammatory compound XPro1595 for Alzheimer’s disease (AD). The trial is currently recruiting in different sites across Australia. More information can be found here. Instead of targeting…
Weight Loss Surgery May Lower Risk of Breast Cancer, Research Suggests
This post was originally published on this site Weight loss surgery may reduce the risk of developing breast cancer in obese individuals, even among those with a genetic predisposition towards cancer, new research suggests. The research was presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) Annual Meeting at ObesityWeek 2019, in a…
Bavencio First-line Maintenance Failed to Extend Survival in Patients with Advanced Gastric and GEJ Cancer
This post was originally published on this site First-line maintenance therapy with Bavencio (avelumab) failed to extend the overall survival of patients with advanced stomach or gastroesophageal junction (GEJ) cancer, as compared to standard care, according to the latest updates of the JAVELIN Gastric 100 clinical trial. The study was a Phase 3, multicenter, open-label…
Venclexta Safe and Effective for Certain Multiple Myeloma Patients, Trial Data Show
This post was originally published on this site Venclexta (venetoclax), approved to treat lymphoma and leukemia, may also be promising for multiple myeloma patients who failed at least one prior treatment, particularly those with a common genetic abnormality called t(11;14) or with high levels of the cell survival protein BCL2, data from two studies suggest. Findings…
Rubraca Reimbursement Approved in Italy for Women With Relapsed Platinum-sensitive Ovarian Cancer
This post was originally published on this site The Italian Medicines Agency (AIFA) has approved Clovis Oncology’s Rubraca (rucaparib) for reimbursement in Italy as a maintenance therapy for women with relapsed ovarian cancer who responded to platinum-based chemotherapy, regardless of their BRCA status. This follows Rubraca’s approval for that indication by the European Commission early this year.…
High Blood Levels of 2 Hormones May Be Linked to Prostate Cancer Development, Study Says
This post was originally published on this site High blood levels of two hormones — insulin-like growth factor-I (IGF-I) and free testosterone — are associated with increased risk of prostate cancer later in life, a new study suggests. The study, “Serum hormones and prostate cancer incidence and mortality in UK Biobank,” was presented at the recent 2019 National…
CHMP Favors Revlimid-Rituximab Combo for Advanced Follicular Lymphoma Patients in EU
This post was originally published on this site A branch of the European Medicines Agency voiced support for Revlimid (lenalidomide) in combination with rituximab becoming a treatment option for adults with follicular lymphoma who responded poorly to, or whose disease returned after, prior therapy. The Committee for Medicinal Products for Human Use (CHMP), an advisory committee for the…